中国智能健康(00348)发布公告，集团预期截至2025年6月30日止六个月取得公司拥有人应占溢利介于约 10万港元至200万港元，而于截至2024年6月30日止六个月则取得公司拥有人应占亏损约2900万港元。 公司拥有人应占亏损转为盈利主要是由于(1)集团于2025半年期间的应收贷款根据预期信贷亏损模型项 下确认的减值亏损拨回约300万港元，而2024半年期间则为减值亏损约600万港元;(2)一般及行政费用从 2024半年期间的约1800万港元减少至2025半年期间的约800万港元，乃由于集团于2025半年期间实施有 效的成本节约措施所致;(3)按公平值计入损益的金融资产的未实现公平值收益于2025半年期间取得约 1200万港元，而2024半年期间则为未实现公平值亏损约500万港元。 ...

內幕消息 正面盈利預告 本公告乃中國智能健康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港 聯合交易所有限公司證券上市規則（「上市規則」）第 13.09(2)(a)條及香港法例第 571章證券及期 貨條例第 XIVA 部內幕消息條文（定義見上市規則）而作出。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根據對本集團截 至二零二五年六月三十日止六個月（「二零二五半年期間」）之未經審核綜合管理賬目之初步評 估，本集團預期錄得之本公司擁有人應佔溢利介乎約 100,000 港元至 2,000,000 港元，而於截至二 零二四年六月三十日止六個月（「二零二四半年期間」）則錄得本公司擁有人應佔虧損約 29,000,000 港元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責 ， 對其準確性或 完整性亦不發表任何聲明 ， 並明確表示 ， 概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任 。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註 ...

（於開曼群島註冊成立之有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 於本公告日期，執行董事為李雄偉先生（主席）、張國偉先生（副主席）、梁奕曦先生、 勞明韵女士、袁輝霞先生及楊強勝先生；以及獨立非執行董事為黎學廉先生及曾展鵬先生。 （股份代號：348） 主席兼執行董事 李雄偉 香港，二零二五年八月十五日 董事會會議召開日期 中國智能健康控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）宣佈本公司董事 會會議將於二零二五年八月二十七日（星期三）舉行，藉以（其中包括）批准刊發本公司 及其附屬公司截至二零二五年六月三十日止六個月的未經審核中期業績，以及考慮派發 中期股息（如適用）以及處理其他事項。 承董事會命 中國智能健康控股有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） (股份代號: 348) 未能符合上市規則第 3.10(1)、3.10A、3.21 及 3.27A 條之規定 茲提述中國智能健康控股有限公司 (「本公司」) 於二零二五年八月一日之公告 (「該公告」) ，內 容有關 (i) 獨立非執行董事辭任；(ii) 董事會委員會組成變更；以及 (iii) 未能符合上市規則第 3.10(1)、3.10A 及 3.21 條的規定。除另有界定外，本公告所用詞彙與該公告所界定者具有相同涵 義。本公司謹此向本公司股東及潛在投資者就該公告提供進一步資料。 除該公告中詳述的未能符合上市規則第 3.10(1)、3.10A 及 3.21 條的規定外，本公司謹此補充自連 先生辭任本公司提名委員會 (「提名委員會」) 成員後，提名委員會由四名 ...

（於開曼群島註冊成立之有限公司） (股份代號: 348) 獨立非執行董事辭任 及 董事會委員會組成變更以 及 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 - 1 - 此外，連先生辭任審計委員會職務後，該委員會的成員減至兩名，未能符合上市規則第 3.21 條的 規定，即審計委員會必須由至少三名非執行董事組成，且大多數為獨立非執行董事。 未能符合上市規則第 3.10(1)、3.10A 及 3.21 條之規定 獨立非執行董事辭任及董事委員會組成變動 中國智能健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，連偉 雄先生（「連先生」）因需更多時間處理其他業務承諾，已辭任本公司獨立非執行董事及審計委 員會（「審計委員會」）、提名委員會及薪酬委員會各自之成員，該辭任自 2025 年 8 月 1 日起生 效。 連先生確認，彼 ...

CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號： 348） 董事名單與其角色和職能 黎學廉先生 曾展鵬先生 董事會設立三個委員會。各董事會成員在這些委員會中所擔任的職位載列如下： 審核委員會 曾展鵬先生（主席） 黎學廉先生 提名委員會 李雄偉先生（主席） 黎學廉先生 曾展鵬先生 勞明韵女士 薪酬委員會 中國智能健康控股有限公司董事（「董事」）會（「董事會」）成員載列如下： 執行董事 李雄偉先生（主席） 張國偉先生（副主席） 梁奕曦先生 勞明韵女士 袁輝霞先生 楊強勝先生 獨立非執行董事 黎學廉先生（主席） 李雄偉先生 曾展鵬先生 香港，二零二五年八月一日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） (股份代號: 348) - 1 - 此外，連先生辭任審計委員會職務後，該委員會的成員減至兩名，未能符合上市規則第 3.21 條的 規定，即審計委員會必須由至少三名非執行董事組成，且大多數為獨立非執行董事。 因此，董事會將按照上市規則的規定，在可行情況下盡快及無論如何於連先生辭任日期起計三個 月內盡力物色合適人選委任為獨立非執行董事，並在必要時任命為審計委員會、提名委員會和薪 酬委員會成員。本公司將於適當時候另行作出公告。 獨立非執行董事辭任 及 董事會委員會組成變更以 及 未能符合上市規則第 3.10(1)、3.10A 及 3.21 條之規定 獨立非執行董事辭任及董事委員會組成變動 中國智能健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國智能健康控股有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00348 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 150,000,000,000 | HKD | 0.01 | HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 150,000,000,000 | HKD | 0.01 | HKD | | 1,500,000,000 | ...

Financial Performance - For the year ended December 31, 2024, the Group's turnover decreased by approximately 22% to approximately HK$114 million, down from approximately HK$146 million in FY23[16] - The gross profit margin for FY24 was approximately 33%, compared to approximately 41% in FY23[17] - The overall loss attributable to owners of the Company was approximately HK$40 million, a decrease from HK$135 million in the corresponding year[17] - The gross profit decreased to approximately HK$37 million for the Reporting Year versus approximately HK$60 million in FY23, with a gross profit margin decrease to approximately 33% (FY23: 41%) due to realized losses from investments and decreased interest income[84] - The Group recorded a revenue decrease of approximately 22% from approximately HK$146 million for the year ended 31 December 2023 to approximately HK$114 million for the year ended 31 December 2024[82] - For the year ended 31 December 2024, the Group recorded a net loss of approximately HK$40 million, a significant improvement compared to a loss of approximately HK$135 million in FY23[97] Revenue Breakdown - Revenue from the investment in financial instruments segment decreased from a net gain of approximately HK$6 million in FY23 to a net loss of less than HK$1 million in FY24[21] - Revenue from the Chinese health products segment decreased from approximately HK$130 million in FY23 to approximately HK$113 million in FY24[21] - Revenue from the money lending segment decreased from approximately HK$11 million in FY23 to approximately HK$1 million in FY24[21] - The Chinese health products business segment recorded a loss (before taxation) of approximately HK$6 million in FY24, compared to a profit of HK$3 million in FY23[23] - The traditional Chinese medicine health products segment generated revenue of approximately HK$113 million, a decline from HK$130 million in FY23, and reported a segment loss of approximately HK$6 million compared to a profit of HK$3 million in FY23[26] - The money lending business generated interest income of approximately HK$1 million, down from HK$11 million in FY23, with a segment loss of approximately HK$10 million compared to a loss of HK$116 million in FY23[29] Economic Environment - The challenging economic environment and changing consumer spending patterns significantly impacted the Group's revenue during FY24[24] - The decrease in revenue from the traditional Chinese medicine segment was attributed to a challenging economic environment and changing consumer spending patterns[26] - Local retail business is expected to face challenges due to inflation, recruitment difficulties, and rising operational costs[59] - The Chinese health products business faced challenges in FY24, with high-end product sales declining by approximately 10% to 34% year-over-year[57] Loan Receivables and Credit Losses - As of December 31, 2024, approximately HK$300 million of loan receivables were classified as stage 3 (credit-impaired), representing about 97% of the gross outstanding balance of loan receivables[29] - The expected credit loss (ECL) recognized during FY24 was approximately HK$2 million, significantly reduced from HK$107 million in FY23[34] - The total gross balance of loan receivables as of December 31, 2024, was approximately HK$308.7 million, with a net amount of approximately HK$8.6 million after ECL allowance[37] - The accumulated allowance for Expected Credit Loss (ECL) on the Group's loan receivables amounted to approximately HK$300 million, an increase from approximately HK$294 million as of December 31, 2023[41] - As of December 31, 2024, loan receivables classified as stage 3 represented 97% of the total gross loan receivable balances, up from 95% in FY23[93] Operational Changes and Strategies - The Group maintained eleven outstanding loans as of December 31, 2024, with two classified under stage 1 and nine under stage 3[34] - The Group plans to enhance the promotion of ready-to-eat health products and collaborate with MAME LAB to introduce maternal health care products, targeting local and younger consumers[63] - The Group will launch on the Xiaohongshu social platform in partnership with Weimob to engage directly with consumers, particularly in the PRC market[63] - The management team has implemented cost control measures and enhanced overseas sourcing efficiency to remain competitive[59] - The Group's strategy includes diversifying revenue sources through investments and acquisitions of promising businesses or projects[69] Financial Position and Assets - The Group's total current assets as of 31 December 2024 were approximately HK$113 million, down from HK$140 million as of 31 December 2023[76] - The Group's total assets as of December 31, 2024, were approximately HK$122 million, down from HK$150 million as of December 31, 2023[117] - The Group's borrowings increased to approximately HK$33 million as of December 31, 2024, compared to approximately HK$29 million as of December 31, 2023[70] - The Group's cash and bank balances were approximately HK$10 million as of December 31, 2024, down from approximately HK$14 million as of December 31, 2023[70] - The Group recorded a decrease in shareholders' funds from approximately HK$4 million as of December 31, 2023 to a net liabilities position of approximately HK$18 million as of December 31, 2024[76] Governance and Compliance - The Company has complied with all code provisions set out in the Corporate Governance Code throughout the year ended December 31, 2024[154] - The Board has focused on empowering and developing employees to create long-term value and sustainable growth for shareholders[155] - The Board emphasizes the importance of establishing a culture of integrity, responsibility, collaboration, teamwork, and customer focus to achieve the Company's objectives[163] - The Company is committed to attracting, retaining, and developing talented employees as part of its strategic objectives[163] - The Company received annual written confirmations of independence from all Independent Non-executive Directors for the year ended December 31, 2024[197]

Financial Performance - China Healthwise Holdings Limited reported total revenue of HKD 146,317,000 for the year ending December 31, 2024, compared to HKD 113,575,000 for the previous year, representing a year-over-year increase of 29%[2] - The gross profit for the year was HKD 37,349,000, down from HKD 60,294,000 in the previous year, indicating a decrease of 38%[2] - The net loss for the year was HKD 40,281,000, compared to a net loss of HKD 134,558,000 in the previous year, showing an improvement of 70%[2] - The basic and diluted loss per share was HKD 0.092 (9 cents), improved from HKD 0.1746 (17.46 cents) in the previous year[4] - For the fiscal year ending December 31, 2024, the company reported a net loss of approximately HKD 40,428,000[9] - The total segment loss before tax for the year ending December 31, 2024, was HKD 22,621,000, compared to a loss of HKD 118,344,000 in 2023, indicating an improvement in performance[20] - The company reported a pre-tax loss of HKD 79,374 million, a decrease from HKD 70,759 million in the previous year[28] - The group recorded a total loss attributable to shareholders of about HKD 40 million for the reporting year, compared to approximately HKD 135 million in fiscal year 2023[61] Revenue and Income Sources - Revenue from major business operations for the year is detailed, with specific figures for customer contract income and other sources of income[15][16] - Customer contract income for the year was reported at HKD 112,832 thousand, compared to HKD 129,523 thousand in the previous year, indicating a decline[16] - External customer revenue for the year ending December 31, 2024, was HKD 113,575,000, a decrease from HKD 146,317,000 in 2023, representing a decline of approximately 22.3%[20] - Revenue from the investment financial instruments segment decreased from a net income of approximately HKD 6 million in the previous fiscal year to a net loss of less than HKD 1 million in the current fiscal year[43] - Revenue from the traditional Chinese medicine health products segment decreased from approximately HKD 130 million in the previous fiscal year to about HKD 113 million in the current fiscal year[43] - The traditional Chinese medicine health products segment contributed approximately HKD 113 million in revenue and incurred a loss of about HKD 6 million before tax in the current fiscal year[44] Assets and Liabilities - As of December 31, 2024, the company's total liabilities amounted to approximately HKD 18,838,000[9] - The company's current assets increased from HKD 113,250,000 in 2023 to HKD 139,655,000 in 2024, representing a growth of approximately 23.3%[5] - The total assets for the reporting segments decreased from HKD 146,778,000 in 2023 to HKD 119,557,000 in 2024, reflecting a reduction of about 18.6%[22] - The total liabilities for the reporting segments decreased from HKD 145,272,000 in 2023 to HKD 140,426,000 in 2024, showing a decline of approximately 3.9%[22] - The company's current and non-current borrowings were HKD 32,572,000 and HKD 63,330,000, respectively[9] - The company's total liabilities amounted to approximately HKD 18.38 million as of December 31, 2024[40] - The debt-to-asset ratio is approximately 79%, compared to 67% on December 31, 2023[71] Cash Flow and Financial Management - The company is implementing measures to improve cash flow, including recovering receivables and cost-saving initiatives[9] - The company aims to meet its operational funding needs through improved cash flow from operations[9] - The board has reviewed the group's cash flow forecast, which covers a period of not less than twelve months from the end of the reporting period[10] - The group believes it will have sufficient working capital to meet its operational and financial obligations for the next twelve months[10] - The group is considering measures to improve cash flow, including recovering outstanding receivables and controlling operational costs[13] - The group anticipates challenges in the lending business environment due to expected high HKD interest rates in 2025, which may deter potential borrowers[67] - The group will closely monitor customer repayment habits and develop action plans for debt recovery as risks increase[67] Operational Efficiency and Cost Management - The company reported a significant increase in operating expenses, with general and administrative expenses rising to HKD 26,414,000 from HKD 37,529,000, a decrease of 30%[2] - Employee costs, including director remuneration, totaled HKD 28,966,000 for the year, with HKD 19,408,000 attributed to the herbal health product segment[23] - Selling and distribution expenses increased to approximately HKD 29 million, a rise of about 4% compared to the previous fiscal year[57] - General and administrative expenses decreased to approximately HKD 26 million from HKD 38 million in fiscal year 2023, attributed to cost-saving measures implemented during the reporting year[58] - Financing costs amounted to approximately HKD 8 million, down from about HKD 9 million in fiscal year 2023[59] Credit Risk and Impairment - The company reported a net impairment loss on receivables of HKD 107,469 million, indicating significant credit risk exposure[24] - The expected credit loss provision for receivables was HKD 300,087,000 in 2024, compared to HKD 294,218,000 in 2023, reflecting an increase in provisions[34] - The expected credit loss model provisions for impairment losses decreased significantly to about HKD 2 million from approximately HKD 107 million in the previous fiscal year[60] - The group recognized an expected credit loss of approximately HKD 2 million for the fiscal year, a decrease from HKD 107 million in the previous fiscal year[50] Market Conditions and Strategic Initiatives - The company faced a challenging economic environment, particularly in local retail, which negatively impacted revenue due to changing consumer spending patterns[45] - The local retail business is expected to face challenges due to inflation, hiring difficulties, and rising operational costs, prompting the management team to implement cost control measures[64] - The group plans to enhance the promotion of convenient health food products, including various herbal teas and health supplements, targeting local consumers and the younger demographic[65] - The company plans to enhance its market presence through new product development and strategic investments in the herbal health product segment[21] - The group aims to diversify its revenue sources through investments or acquisitions of businesses with broad prospects[69]